Company Update: Alexion Pharmaceuticals Inc (NASDAQ:ALXN) – Alexion to Present at the Leerink Partners 5th Annual Global Healthcare Conference

[Business Wire] – Alexion Pharmaceuticals, Inc. today announced that management will present at the Leerink Partners 5th Annual Global Healthcare Conference on Thursday, February 11, 2016 at 1:50 p.m., Eastern Time. Read more on this. Alexion Pharmaceuticals, Inc. (ALXN) , valued at $33.08B, started the session at $143.81. A quick look at the market, the company’s stock traded between $143.81 and $152.41 and has traded between $130.51 and $208.88 over the past 12 months. ALXN shares are currently priced at 27.44x this year’s forecasted earnings, which makes them relatively expensive compared to the industry ’s -6.28x earnings multiple. Consensus earnings for the current quarter by the 14 sell-side analysts covering the stock is an estimate of $1.15 per share, which would be $0.13 worse than the year-ago quarter and a $0.04 sequential decrease. The full-year EPS estimate is $5.32, which would be a $0.33 better than last year. The quarterly earnings estimate is predicated on a consensus revenue forecast of $718.46 Million. If reported, that would be a 19.68% increase over the year-ago quarter. More recently, Credit Suisse Initiated ALXN at Neutral (Jan 20, 2016). Previously, Sun Trust Rbsn Humphrey Initiated ALXN at to Buy. The average price target for ALXN shares by the analysts covering it is $213.50, which is 48.46% above where the stock opened. See more in (NASDAQ:ALXN) Similar Articles: Stock Update: Alexion Pharmaceuticals Inc (NASDAQ:ALXN) – Alexion Pharmaceuticals to Report Fourth Quarter and Full Year 2015 Results on Wednesday, February 3, 2016 Stock Update: Alexion Pharmaceuticals Inc (NASDAQ:ALXN) – Healthcare Sector Stocks under Review – Celldex Therapeutics, Alexion Pharmaceuticals, Advaxis, BioDelivery Sciences and Cytori Therapeutics Stock Update (NASDAQ:ALXN): Alexion to Present at the 2015 Morgan Stanley Global Healthcare Conference